Endemic SARS-CoV-2 will maintain post-pandemic immunity
- 5 January 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 21 (3), 131-132
- https://doi.org/10.1038/s41577-020-00493-9
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Robust neutralizing antibodies to SARS-CoV-2 infection persist for monthsScience, 2020
- Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onsetEuropean Journal of Immunology, 2020
- Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral ImmunityImmunity, 2020
- The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunityPublished by Cold Spring Harbor Laboratory ,2020
- Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York CityNature, 2020
- Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patientsScience Immunology, 2020
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severityNature Communications, 2020
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Infectious Bronchitis Virus Variants: Molecular Analysis and Pathogenicity InvestigationInternational Journal of Molecular Sciences, 2017